Fiorentino, Francesco https://orcid.org/0000-0003-3550-1860
Cervoni, Matteo https://orcid.org/0000-0002-4292-2615
Wang, Yi
Urner, Leonhard H. https://orcid.org/0000-0001-8144-8955
Sauer, Joshua B.
Tran, Anh
Corey, Robin A. https://orcid.org/0000-0003-1820-7993
Rotili, Dante
Mai, Antonello https://orcid.org/0000-0001-9176-2382
Stansfeld, Phillip J. https://orcid.org/0000-0001-8800-7669
Imperi, Francesco https://orcid.org/0000-0001-5080-5665
Yu, Edward W. https://orcid.org/0000-0001-5912-1227
Su, Chih-Chia https://orcid.org/0000-0003-3646-327X
Robinson, Carol V. https://orcid.org/0000-0001-7829-5505
Bolla, Jani R. https://orcid.org/0000-0003-4346-182X
Funding for this research was provided by:
Royal Society (URF\R1\211567)
RCUK | Engineering and Physical Sciences Research Council (EP/Y036158/1)
RCUK | Engineering and Physical Sciences Research Council (EP/T022108/1)
RCUK | Medical Research Council (MR/V028839/1)
RCUK | Medical Research Council (MR/Z504245/1)
American Heart Association (25CDA1455062)
Wellcome Trust (208361/Z/17/Z)
RCUK | Biotechnology and Biological Sciences Research Council (BB/P01948X/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/Y003187/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/Y003306/1)
Article History
Received: 21 July 2025
Accepted: 29 October 2025
First Online: 17 December 2025
Competing interests
: C.V.R. is the founder and consultant of OMass Therapeutics. All other authors have no competing interests.